• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cell Therapy Services

Cell Therapy Services

We offer an integrated CAR T-cell therapy research and development services ranging from antibody discovery, novel CAR designing, pre-clinical studies to clinical development.

Chimeric Antigen Receptor T (CAR T) are T-cells that are genetically engineered and are used in cell therapy. Our expert team of scientists is committed to provide a wide range of services in CAR T-cell therapy research.

Speak to our experts

CAR Designing

  • CAR discovery (scFv / vHH) and screening
  • 2nd / 3rd / 4th generation CARs designing (ScFV /vHH / linkers/co-stimulatory domain testing / safety switches / standard designs)
  • Dual/bi-specific CAR and universal / allogeneic CARs

CAR T Generation

  • Viral vector system (lentivirus/retrovirus)
  • Non-viral system (synthetic mRNA/ transposon)
  • Transduction/transfection of primary T-cells from healthy donors

CAR T Manufacturing Process Optimization

  • Media, cytokines and growth factors screening for ex vivo CAR T-cell manufacturing process optimization

CAR T Characterization

  • CAR detection (% CAR+ T-cells) by flow cytometry
  • Vector copy number (VCN) by ddPCR/ qRT-PCR
  • Immunophenotyping (%CD3+/%CD4+, (%CD3+/%CD8+ CAR-T cells), %TN, %TSCM, %TCM, %TEM and %TE during and after ex vivo CAR-T expansion
  • Activation (CD25) and exhaustion marker (PD-1, LAG-3, TIM3, CTLA-4) analysis

In vitro CAR T Screening

  • CAR-T proliferation (recombinant protein or co-culture (E:T) assay)
  • Cytotoxicity assay /co-culture (different E:T ratio) using target expressing parental or reporter cell lines
  • T-cell activation (CD25) marker analysis
  • T-cell exhaustion marker analysis (PD-1, LAG-3, TIM3, CTLA-4)
  • Inflammatory cytokine profiling (IL-2, IFN-y and TNF-a, CD107 a/b)

In vivo CAR T Efficacy

  • Tumor clearance study in orthotopic systemic NOD-SCID xenograft model (B-cell malignancies)
  • Immunophenotyping of circulation CAR-T cells
  • CAR-T activation, proliferation and persistence assessment by flow cytometry and Vector Copy Number (VCN) analysis
  • Cytokine profiling (IL-2, IFN-y and TNF-a)

Reagent Generation for CAR T

  • Lentivirus, retrovirus, synthetic mRNA, transposon system, KI/KO cell lines and reagent proteins

Why Aurigene Pharmaceutical Services?

CAR discovery

CAR designing and screening

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack